Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 8/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | PGR | P06401 | 3/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.73 |
| ▸ | IL5 | P05113 | 1/20 | 0.73 |
| ▸ | AR | P10275 | 1/20 | 0.73 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | MMP9 | P14780 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7735905 | 0.95 | HIF1A (0.66) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 | |
| SCHEMBL2020336 | 0.93 | HIF1A (0.62) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 | |
| SCHEMBL7735918 | 0.90 | ALDH1A1 (0.64) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 | |
| SCHEMBL13654495 | 0.89 | HIF1A (0.63) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 | |
| Dexbudesonide SCHEMBL8159866 | 0.88 | NR3C1 (0.78) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 | |
| SCHEMBL2017765 | 0.88 | NR3C1 (0.57) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 | |
| Dexbudesonide SCHEMBL8513617 | 0.87 | NR3C1 (0.75) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 | |
| SCHEMBL10539776 | 0.86 | NR3C1 (0.74) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 | |
| SCHEMBL8500349 | 0.86 | NR3C1 (0.74) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 | |
| SCHEMBL10538489 | 0.86 | NR3C1 (0.74) | NR3C1HIF1ANR3C2CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116106439-B | Method for simultaneously detecting multiple genotoxic impurities in medicine | 上海方予健康医药科技有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-116136523-A | Separation detection method for formoterol powder fog agent content of budesonide fumarate | 苏州易合医药有限公司 | 2023-05-19 | — | — | CN | claimed |
| CN-116106439-A | Method for simultaneously detecting multiple genotoxic impurities in medicine | 上海方予健康医药科技有限公司 | 2023-05-12 | — | — | CN | claimed |
| EP-0502092-B1 | ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | DRACO AB (SE) | 1995-07-26 | — | — | EP | claimed |
| CN-116106439-B | Method for simultaneously detecting multiple genotoxic impurities in medicine | 上海方予健康医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-116106439-B | Method for simultaneously detecting multiple genotoxic impurities in medicine | 上海方予健康医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119224177-A | Impurity analysis method for budesonide inhalation solution | 浙江福瑞喜药业有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119224177-A | Impurity analysis method for budesonide inhalation solution | 浙江福瑞喜药业有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-117571884-A | High performance liquid chromatography detection method for substances related to budesonide lotion | 南京科默生物医药有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-116136523-A | Separation detection method for formoterol powder fog agent content of budesonide fumarate | 苏州易合医药有限公司 | 2023-05-19 | — | — | CN | disclosed |
| CN-116106439-A | Method for simultaneously detecting multiple genotoxic impurities in medicine | 上海方予健康医药科技有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-116106439-A | Method for simultaneously detecting multiple genotoxic impurities in medicine | 上海方予健康医药科技有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-113444137-B | Method for synthesizing 16, 21-cyclic hemiacetal of 17-deoxyprednisolone | 成都倍特药业股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-113444137-B | Method for synthesizing 16, 21-cyclic hemiacetal of 17-deoxyprednisolone | 成都倍特药业股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| US-20110160167-A1 | Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160167-A1 | Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160167-A1 | Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-6423340-B1 | GASTROINTESTINAL DISORDERS, CROHN'S COLITIS | AKTIEBOLAGET DRACO (SE) | 2002-07-23 | — | — | US | disclosed |
| US-5643602-A | TIME RELEASE PELLETS FOR INTESTINES | ASTRA AKTIEBOLAG (SE) | 1997-07-01 | — | — | US | disclosed |
| EP-0502092-B1 | ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | DRACO AB (SE) | 1995-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160167-A1 | Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists | NR3C1, NR3C2, MC2R | NR3C1 1/4885HIF1A 3437/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.